JP2019513752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513752A5 JP2019513752A5 JP2018552826A JP2018552826A JP2019513752A5 JP 2019513752 A5 JP2019513752 A5 JP 2019513752A5 JP 2018552826 A JP2018552826 A JP 2018552826A JP 2018552826 A JP2018552826 A JP 2018552826A JP 2019513752 A5 JP2019513752 A5 JP 2019513752A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- therapeutic
- disease
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims 1
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035806 respiratory chain Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319580P | 2016-04-07 | 2016-04-07 | |
| US62/319,580 | 2016-04-07 | ||
| US201662328484P | 2016-04-27 | 2016-04-27 | |
| US62/328,484 | 2016-04-27 | ||
| PCT/US2017/026675 WO2017177178A1 (en) | 2016-04-07 | 2017-04-07 | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513752A JP2019513752A (ja) | 2019-05-30 |
| JP2019513752A5 true JP2019513752A5 (OSRAM) | 2020-05-21 |
Family
ID=60000683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552826A Pending JP2019513752A (ja) | 2016-04-07 | 2017-04-07 | 神経変性疾患を治療するためのｔｄｐ−４３のミトコンドリア局在化阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11124553B2 (OSRAM) |
| EP (1) | EP3440094B1 (OSRAM) |
| JP (1) | JP2019513752A (OSRAM) |
| KR (1) | KR20180132807A (OSRAM) |
| CN (1) | CN109563130A (OSRAM) |
| AU (1) | AU2017248353A1 (OSRAM) |
| CA (1) | CA3020344A1 (OSRAM) |
| SG (1) | SG11201808829VA (OSRAM) |
| WO (1) | WO2017177178A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4467196A3 (en) | 2017-06-28 | 2025-06-25 | The Cleveland Clinic Foundation | Treatment of nervous system injury and neurodegenerative disorders and related conditions |
| CN113683703B (zh) * | 2020-05-18 | 2023-08-15 | 中国人民解放军陆军军医大学第二附属医院 | 一种hTERT靶向物及其用途 |
| WO2021247893A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Bicyclic heteroaromatic amide compounds and uses thereof |
| CN114057858B (zh) * | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽 |
| KR102488166B1 (ko) | 2020-09-24 | 2023-01-13 | 재단법인대구경북과학기술원 | Ｈｄａｃ６의 ｔｄｐ－４３ 단백질병증 예방 또는 치료제로서의 용도 |
| JP6961278B1 (ja) * | 2021-03-10 | 2021-11-05 | 国立研究開発法人量子科学技術研究開発機構 | 生体試料中のｔｄｐ−４３を測定する方法及び装置 |
| CN113450336B (zh) * | 2021-07-01 | 2022-10-25 | 维柯基科技(上海)有限公司 | 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质 |
| KR20240133923A (ko) * | 2023-02-28 | 2024-09-05 | (주)케어젠 | 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물 |
| KR102859015B1 (ko) | 2023-07-20 | 2025-09-12 | 충북대학교 산학협력단 | ｃＡｂｌ에 의한 ＴＤＰ４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법 |
| WO2025152803A1 (zh) * | 2024-01-17 | 2025-07-24 | 四川大学 | 一种靶向traf6的多肽及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5858683A (en) * | 1996-08-30 | 1999-01-12 | Matritech, Inc. | Methods and compositions for the detection of cervical cancer |
| GB9718609D0 (en) | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
| GB9723824D0 (en) * | 1997-11-11 | 1998-01-07 | Actinova Ltd | Cytostatic agents |
| US6841535B2 (en) | 2000-07-31 | 2005-01-11 | Active Motif | Peptide-mediated transfection agents and methods of use |
| US20040229837A1 (en) * | 2003-05-15 | 2004-11-18 | Yijuang Chern | Treatment of neurodegenerative diseases |
| JP2009503439A (ja) * | 2005-07-01 | 2009-01-29 | アルボー ビータ コーポレーション | ウイルス感染および細菌感染の診断および処置のための方法および組成物 |
| EP2097090B1 (en) * | 2006-12-06 | 2014-10-29 | Thomas Jefferson University | Peptide and treatment for hiv-1 infection |
| CA2713871C (en) * | 2008-02-01 | 2018-05-22 | Washington University In St. Louis | Sequences associated with tdp-43 proteinopathies and methods of using the same |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US9926353B2 (en) * | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| EP2821504A4 (en) * | 2012-02-28 | 2016-02-17 | Univ Tokyo Nat Univ Corp | METHOD FOR DETERMINING A DISEASE RELATED TO TDP-43 CONCENTRATION IN CELLS |
| US9017672B2 (en) * | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
| WO2013192298A1 (en) * | 2012-06-22 | 2013-12-27 | The Scripps Research Institute | Apoptosis biomarkers |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
-
2017
- 2017-04-07 AU AU2017248353A patent/AU2017248353A1/en not_active Abandoned
- 2017-04-07 SG SG11201808829VA patent/SG11201808829VA/en unknown
- 2017-04-07 KR KR1020187031919A patent/KR20180132807A/ko not_active Ceased
- 2017-04-07 JP JP2018552826A patent/JP2019513752A/ja active Pending
- 2017-04-07 CA CA3020344A patent/CA3020344A1/en not_active Abandoned
- 2017-04-07 US US16/090,786 patent/US11124553B2/en active Active
- 2017-04-07 WO PCT/US2017/026675 patent/WO2017177178A1/en not_active Ceased
- 2017-04-07 CN CN201780028382.0A patent/CN109563130A/zh active Pending
- 2017-04-07 EP EP17779936.8A patent/EP3440094B1/en active Active
-
2021
- 2021-09-21 US US17/480,884 patent/US12129285B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513752A5 (OSRAM) | ||
| JP2013172743A5 (OSRAM) | ||
| JPWO2019156137A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2012115277A5 (OSRAM) | ||
| JP2016525095A5 (ja) | 環状ポリペプチド | |
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| JP2015529685A5 (OSRAM) | ||
| JP2012176978A5 (OSRAM) | ||
| JP2017158561A5 (OSRAM) | ||
| JP2013520405A5 (OSRAM) | ||
| JP2012501973A5 (OSRAM) | ||
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| JP2014510101A5 (OSRAM) | ||
| JPWO2019107530A5 (OSRAM) | ||
| JP2014514365A5 (OSRAM) | ||
| JP2013533273A5 (OSRAM) | ||
| JP2015510393A5 (OSRAM) | ||
| WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| JP2013523718A5 (OSRAM) | ||
| RU2017121836A (ru) | Нейродегенеративные расстройства | |
| JP2019531293A5 (OSRAM) | ||
| JP2014529399A5 (OSRAM) | ||
| CN110799522A (zh) | 用于治疗、改善或预防脑出血的肽及其用途 |